Anti-mitochondrial M5 type antibody represents one of the serological markers for anti-phospholipid syndrome distinct from anti-cardiolipin and anti-b2-glycoprotein I antibodies

L. La Rosa, G. Covini, C. Galperin, L. Catelli, N. Del Papa, G. Reina, A. Morabito, G. Balestrieri, A. Tincani, M. E. Gershwin, P. L. Meroni

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The aim of this study was to characterize the antigen specificity and to evaluate the diagnostic and prognostic value of anti-mitochondrial M5 type antibodies (AMA M5). Fifty-eight patients selected on the basis of their AMA M5 positivity were investigated in relationship to their clinical and serological profile. Cross-absorption studies, Western blotting and immunoprecipitation analysis were carried out for AMA M5 antigen specificity characterization. Most patients had a diagnosis of systemic lupus erythematosus (SLE) (65.5%) or of primary anti-phospholipid syndrome (PAPS) (24%); all the patients were positive for IgG or IgM anti-cardiolipin (anti- CL) antibodies and 49% of them also displayed lupus anticoagulant (LA) activity. Anti-β2-glycoprotein I (β2-GPI) IgG were detectable in 30/38 sera (78.9%) and IgM in 34/38 (89.4%). While anti-CL and anti-β2-GPI IgG antibodies were significantly associated with history of thrombosis and fetal loss, AMA M5 displayed a statistical association only for thrombocytopenia and recurrent fetal loss. Absorption with human β2-GPI both in free solution or in solid phase as well as with CL liposomes or CL/β2-GPI liposome complexes did not affect AMA M5 fluorescence. While AMA M5 activity is absorbed by whole mitochondrial preparations, no specific reactivities against several human, bovine and rat mitochondrial proteins could be detected in Western blotting and immunoprecipitation studies. AMA M5 appear to he detectable in both primary and secondary APS, displaying a strong association with the presence of thrombocytopenia and fetal loss. Although strictly related to anti-phospholipid antibodies, AMA M5, anti-CL and anti- β2-GPI antibodies represent distinct serological markers of the APS.

Original languageEnglish
Pages (from-to)144-151
Number of pages8
JournalClinical and Experimental Immunology
Volume112
Issue number1
DOIs
Publication statusPublished - 1998

Fingerprint

Cardiolipins
Antiphospholipid Syndrome
Glycoproteins
Antibodies
Anti-Idiotypic Antibodies
Immunoglobulin G
Immunoprecipitation
Liposomes
Thrombocytopenia
Immunoglobulin M
Western Blotting
Antigens
Lupus Coagulation Inhibitor
Antibody Specificity
Mitochondrial Proteins
Systemic Lupus Erythematosus
Phospholipids
Thrombosis
Fluorescence
Serum

Keywords

  • Anti-β-glycoprotein I antibodies
  • Anti-mitochondrial M5 antibodies
  • Anti-phospholipid syndrome
  • Fetal loss
  • Thrombocytopenia
  • Thrombosis

ASJC Scopus subject areas

  • Immunology

Cite this

Anti-mitochondrial M5 type antibody represents one of the serological markers for anti-phospholipid syndrome distinct from anti-cardiolipin and anti-b2-glycoprotein I antibodies. / La Rosa, L.; Covini, G.; Galperin, C.; Catelli, L.; Del Papa, N.; Reina, G.; Morabito, A.; Balestrieri, G.; Tincani, A.; Gershwin, M. E.; Meroni, P. L.

In: Clinical and Experimental Immunology, Vol. 112, No. 1, 1998, p. 144-151.

Research output: Contribution to journalArticle

La Rosa, L. ; Covini, G. ; Galperin, C. ; Catelli, L. ; Del Papa, N. ; Reina, G. ; Morabito, A. ; Balestrieri, G. ; Tincani, A. ; Gershwin, M. E. ; Meroni, P. L. / Anti-mitochondrial M5 type antibody represents one of the serological markers for anti-phospholipid syndrome distinct from anti-cardiolipin and anti-b2-glycoprotein I antibodies. In: Clinical and Experimental Immunology. 1998 ; Vol. 112, No. 1. pp. 144-151.
@article{a08877d279534c01a411e7944f2e6525,
title = "Anti-mitochondrial M5 type antibody represents one of the serological markers for anti-phospholipid syndrome distinct from anti-cardiolipin and anti-b2-glycoprotein I antibodies",
abstract = "The aim of this study was to characterize the antigen specificity and to evaluate the diagnostic and prognostic value of anti-mitochondrial M5 type antibodies (AMA M5). Fifty-eight patients selected on the basis of their AMA M5 positivity were investigated in relationship to their clinical and serological profile. Cross-absorption studies, Western blotting and immunoprecipitation analysis were carried out for AMA M5 antigen specificity characterization. Most patients had a diagnosis of systemic lupus erythematosus (SLE) (65.5{\%}) or of primary anti-phospholipid syndrome (PAPS) (24{\%}); all the patients were positive for IgG or IgM anti-cardiolipin (anti- CL) antibodies and 49{\%} of them also displayed lupus anticoagulant (LA) activity. Anti-β2-glycoprotein I (β2-GPI) IgG were detectable in 30/38 sera (78.9{\%}) and IgM in 34/38 (89.4{\%}). While anti-CL and anti-β2-GPI IgG antibodies were significantly associated with history of thrombosis and fetal loss, AMA M5 displayed a statistical association only for thrombocytopenia and recurrent fetal loss. Absorption with human β2-GPI both in free solution or in solid phase as well as with CL liposomes or CL/β2-GPI liposome complexes did not affect AMA M5 fluorescence. While AMA M5 activity is absorbed by whole mitochondrial preparations, no specific reactivities against several human, bovine and rat mitochondrial proteins could be detected in Western blotting and immunoprecipitation studies. AMA M5 appear to he detectable in both primary and secondary APS, displaying a strong association with the presence of thrombocytopenia and fetal loss. Although strictly related to anti-phospholipid antibodies, AMA M5, anti-CL and anti- β2-GPI antibodies represent distinct serological markers of the APS.",
keywords = "Anti-β-glycoprotein I antibodies, Anti-mitochondrial M5 antibodies, Anti-phospholipid syndrome, Fetal loss, Thrombocytopenia, Thrombosis",
author = "{La Rosa}, L. and G. Covini and C. Galperin and L. Catelli and {Del Papa}, N. and G. Reina and A. Morabito and G. Balestrieri and A. Tincani and Gershwin, {M. E.} and Meroni, {P. L.}",
year = "1998",
doi = "10.1046/j.1365-2249.1998.00562.x",
language = "English",
volume = "112",
pages = "144--151",
journal = "Clinical and Experimental Immunology",
issn = "0009-9104",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Anti-mitochondrial M5 type antibody represents one of the serological markers for anti-phospholipid syndrome distinct from anti-cardiolipin and anti-b2-glycoprotein I antibodies

AU - La Rosa, L.

AU - Covini, G.

AU - Galperin, C.

AU - Catelli, L.

AU - Del Papa, N.

AU - Reina, G.

AU - Morabito, A.

AU - Balestrieri, G.

AU - Tincani, A.

AU - Gershwin, M. E.

AU - Meroni, P. L.

PY - 1998

Y1 - 1998

N2 - The aim of this study was to characterize the antigen specificity and to evaluate the diagnostic and prognostic value of anti-mitochondrial M5 type antibodies (AMA M5). Fifty-eight patients selected on the basis of their AMA M5 positivity were investigated in relationship to their clinical and serological profile. Cross-absorption studies, Western blotting and immunoprecipitation analysis were carried out for AMA M5 antigen specificity characterization. Most patients had a diagnosis of systemic lupus erythematosus (SLE) (65.5%) or of primary anti-phospholipid syndrome (PAPS) (24%); all the patients were positive for IgG or IgM anti-cardiolipin (anti- CL) antibodies and 49% of them also displayed lupus anticoagulant (LA) activity. Anti-β2-glycoprotein I (β2-GPI) IgG were detectable in 30/38 sera (78.9%) and IgM in 34/38 (89.4%). While anti-CL and anti-β2-GPI IgG antibodies were significantly associated with history of thrombosis and fetal loss, AMA M5 displayed a statistical association only for thrombocytopenia and recurrent fetal loss. Absorption with human β2-GPI both in free solution or in solid phase as well as with CL liposomes or CL/β2-GPI liposome complexes did not affect AMA M5 fluorescence. While AMA M5 activity is absorbed by whole mitochondrial preparations, no specific reactivities against several human, bovine and rat mitochondrial proteins could be detected in Western blotting and immunoprecipitation studies. AMA M5 appear to he detectable in both primary and secondary APS, displaying a strong association with the presence of thrombocytopenia and fetal loss. Although strictly related to anti-phospholipid antibodies, AMA M5, anti-CL and anti- β2-GPI antibodies represent distinct serological markers of the APS.

AB - The aim of this study was to characterize the antigen specificity and to evaluate the diagnostic and prognostic value of anti-mitochondrial M5 type antibodies (AMA M5). Fifty-eight patients selected on the basis of their AMA M5 positivity were investigated in relationship to their clinical and serological profile. Cross-absorption studies, Western blotting and immunoprecipitation analysis were carried out for AMA M5 antigen specificity characterization. Most patients had a diagnosis of systemic lupus erythematosus (SLE) (65.5%) or of primary anti-phospholipid syndrome (PAPS) (24%); all the patients were positive for IgG or IgM anti-cardiolipin (anti- CL) antibodies and 49% of them also displayed lupus anticoagulant (LA) activity. Anti-β2-glycoprotein I (β2-GPI) IgG were detectable in 30/38 sera (78.9%) and IgM in 34/38 (89.4%). While anti-CL and anti-β2-GPI IgG antibodies were significantly associated with history of thrombosis and fetal loss, AMA M5 displayed a statistical association only for thrombocytopenia and recurrent fetal loss. Absorption with human β2-GPI both in free solution or in solid phase as well as with CL liposomes or CL/β2-GPI liposome complexes did not affect AMA M5 fluorescence. While AMA M5 activity is absorbed by whole mitochondrial preparations, no specific reactivities against several human, bovine and rat mitochondrial proteins could be detected in Western blotting and immunoprecipitation studies. AMA M5 appear to he detectable in both primary and secondary APS, displaying a strong association with the presence of thrombocytopenia and fetal loss. Although strictly related to anti-phospholipid antibodies, AMA M5, anti-CL and anti- β2-GPI antibodies represent distinct serological markers of the APS.

KW - Anti-β-glycoprotein I antibodies

KW - Anti-mitochondrial M5 antibodies

KW - Anti-phospholipid syndrome

KW - Fetal loss

KW - Thrombocytopenia

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=15644370081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15644370081&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2249.1998.00562.x

DO - 10.1046/j.1365-2249.1998.00562.x

M3 - Article

VL - 112

SP - 144

EP - 151

JO - Clinical and Experimental Immunology

JF - Clinical and Experimental Immunology

SN - 0009-9104

IS - 1

ER -